MedPath

Decline of mentale functions in adults with Down Syndrome: clinical and experimental study on the effects of treatment with fluoxetine and of cognitive and physical training.

Conditions
Adults (over 30 years) with Down Syndrome.
MedDRA version: 14.1Level: LLTClassification code 10040442Term: Severe imbecilitySystem Organ Class: 10029205 - Nervous system disorders
MedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Registration Number
EUCTR2011-001556-11-IT
Lead Sponsor
IRCCS FONDAZIONE STELLA MARIS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Inclusion criteria are: 1) SD 2) subjects of both sexes and older than 30 years 3) signing of informed consent by the parent or legal tutor of the patient.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 38
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 2

Exclusion Criteria

Exclusion criteria are: 1) the presence of clinical signs of dementia at the first valuation, 2) drugs that may interact with fluoxetine (Monoamine Oxidase, Phenytoin, serotonergic drugs, lithium and tryptophan, oral anticoagulants, Electroconvulsive Therapy, drugs that interact with the CYP2D6 isoenzyme system in the liver), 3) medical conditions that are contraindicated for treatment with fluoxetine (Mania, Hepatic and renal failure, diabetes, Akathisia / psychomotor restlessness, bleeding disorders, epilepsy), 4) established pregnancy (the pregnancy will be investigated in females of childbearing age through the declaration of the person and / or tutor).

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath